268P - Sarcopenia may be associated with the mortality in patients with hepatocellular carcinoma

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Hepatobiliary Cancers
Palliative Care
Presenter Sung Eun Kim
Citation Annals of Oncology (2016) 27 (suppl_9): ix68-ix85. 10.1093/annonc/mdw582
Authors S.E. Kim, J.W. Park, C.K. Park
  • Internal Medicine, Hallym University Sacred Heart Hospital, 431-070 - Anyang/KR



Sarcopenia has known as an independent predictor of clinical outcomes in patients with hepatocellular carcinoma (HCC). In this study, we aimed to investigate the association of sarcopenia with the mortality in patients with HCC.


A total of 193 HCC patients were subjected. All enrolled patients had a computed tomography at the level of the third lumbar (L3) vertebrae to determine the L3 skeletal muscle index. Sarcopenia was defined using previously established cutpoints. They were followed up for a median 12 months (range, 1-80).


Median age was 58 years (range, 36-86), 80% of patients were male, 62% Child –Pugh class A and 70% were positive for HBsAg. Only 23 patients (12%) could undergo curative treatment (surgical resection, liver transplantation, radiofrequency ablation) Sacopenia was present in 106 patients (55%). By univariate analysis, sarcopenia (OR = 2.08; 95% CI 1.12-3.87: P = 0.021), Child-Pugh score (OR = 1.38; 95% CI 0.92-191.12: P 


Our data suggested that sarcopenia and curative treatment of HCC may be closely associated with the mortality in HCC patients.

Clinical trial indentification

Legal entity responsible for the study





All authors have declared no conflicts of interest.